FDA Backtracks Over GLP-1s' Effects on Pancreas

| Mar 4, 2014

The U.S. Food and Drug Administration reports that its review of various animal and human studies does not show a link between GLP-1 drugs used to treat type 2 diabetes and pancreatic maladies, including acute pancreatitis and pancreatic cancer.

GLP-1 drugs, which work by stimulating the body to produce insulin, include Bristol-Myers Squibb's Byetta and Bydureon, Merck's Januvia and Janumet, and Novo Nordisk's Victoza.

However, the agency says that it has not reached a final conclusion about the drugs' safety and will continue to study them for adverse effects. In the meantime, GLP-1 drugs' labels will continue to carry the FDA-mandated warnings about possible effects on the pancreas.

What's interesting about the FDA decision is that it's indicative of an agency that approached a perceived problem using bad science and is now backtracking.

When concerns about Byetta, the first GLP-1 drug to hit the U.S. market, began surfacing in 2008, the agency focused on one statistic: Out of a conservatively estimated 700,000 users of Byetta, 36 had developed acute pancreatitis, from which four had died. This, said the FDA, was cause to look into issuing a black box warning for the drug.

A black box warning alerts users that the FDA considers a drug to pose a significant risk of adverse effects. In a way it's like Internet sites that warn visitors about disturbing content and offer them a yes/no option for entering--"Proceed at your own risk.")

At the time, Diabetes Health pointed out the near absurdity of sounding an alarm over the possibility that one out of approx. every 19,000 users of Byetta had developed pancreatitis as the result of taking the drug, and one out of every 175,000 had died from it.

In its backtrack, the FDA cited insurance statistics as the cause of its initial concern. At the time that the agency began scrutinizing Byetta, which had become one of the most popular and successful type 2 drugs in history, other pharma industry observers were already disputing the GLP-1-pancreatitis connection (see first link below).

(One critic of our 2008 article pointing out the ludicrousness of the FDA statistics said that it was possible that many Byetta-related cases of pancreatitis had gone unreported or not been connected to the drug. But, since we couldn't work with imaginary numbers, we decided it was fair to comment on the FDA's own statistics--the statistics upon which it was basing a crucial labeling decision.)

Aside from the appallingly small statistical sample that the FDA based its alarm on, one critic noted that people with type 2 diabetes already run an increased risk of pancreatic problems regardless of the drugs they take.

Adding to the problems for Byetta that the agency's ill-advised warnings created was the media's unquestioning characterization of the drug as posing risks, with even the prestigious Wall Street Journal labeling the drug "controversial," while providing no supporting evidence for the FDA's assertion.

Links to previous Diabetes Health articles on this topic:



Click Here To View Or Post Comments

Categories: Acute Pancreatitis, Black Box, Bristol-Myers Squibb, Bydureon, Byetta, FDA, GLP-1 Drugs, Janumet, Januvia, Merck, Novo Nordisk, Victoza

Take the Diabetes Health Pump Survey
See What's Inside
Read this FREE issue now
For healthcare professionals only

You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View

See if you qualify for our free healthcare professional magazines. Click here to start your application for Pre-Diabetes Health, Diabetes Health Pharmacist and Diabetes Health Professional.

Learn More About the Professional Subscription

Free Diabetes Health e-Newsletter

Top Rated
Print | Email | Share | Comments (0)

You May Also Be Interested In...


Add your comments about this article below. You can add comments as a registered user or anonymously. If you choose to post anonymously your comments will be sent to our moderator for approval before they appear on this page. If you choose to post as a registered user your comments will appear instantly.

When voicing your views via the comment feature, please respect the Diabetes Health community by refraining from comments that could be considered offensive to other people. Diabetes Health reserves the right to remove comments when necessary to maintain the cordial voice of the diabetes community.

For your privacy and protection, we ask that you do not include personal details such as address or telephone number in any comments posted.

Don't have your Diabetes Health Username? Register now and add your comments to all our content.

Have Your Say...

Username: Password:
©1991-2014 Diabetes Health | Home | Privacy | Press | Advertising | Help | Contact Us | Donate | Sitemap

Diabetes Health Medical Disclaimer

The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.